Austrian Breast & Colorectal Cancer Study Group

Science from the heart of Europe

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Cristina Saura, Dominik Hlauschek, Mafalda Oliveira, Dimitrios Zardavas, Anita Jallitsch-Halper, Lorena de la Peña, Paolo Nuciforo, Alberto Ballestrero, Peter Dubsky, Janine M Lombard, Peter Vuylsteke, Carlos A Castaneda, Marco Colleoni, Giuliano Santos Borges, Eva Ciruelos, Monica Fornier, Katalin Boer, Aditya Bardia, Timothy R Wilson, Thomas J Stout, Jerry Y Hsu, Yi Shi, Martine Piccart, Michael Gnant, José Baselga, Evandro de Azambuja

Lancet Oncology, published online August 8, 2019.

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30334-1/fulltext

---

Prediction of distant recurrence using EndoPredict amon women with ER+, HER2- node-positive and node-negative breast cancer treated with endocrine therapy only

Martin Filipits, Peter Dubsky, Margaretha Rudas, Richard Greil, Marija Balic, Zsuzsanna Bago-Horvath, Christian F. Singer, Dominik Hlauschek, Krystal Brown, Ryan Bernhisel, Ralf Kronenwett, Jonathan M. Lancaster, Florian Fitzal, and Michael Gnant

Clinical Cancer Research, published online May 7, 2019.

https://www.ncbi.nlm.nih.gov/pubmed/31064782

---

Stromal coexpression of uPA/PAI-1 protein predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer

Christian F. Singer, Martin Filipits, Stephan W. Jahn, Luca Abete, Raimund Jakesz, Richard Greil, Thomas Bauernhofer, Werner Kwasny, Michael Seifert, Florian Fitzal, Marie-Therese Kastner, Manfred Schmitt, Farid Moinfar, Michael Gnant

The Breast, veröffentlicht online am 03. Mai 2019.

https://www.ncbi.nlm.nih.gov/pubmed/31132475

---

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone

Ivana Sestak, Miguel Martín, Peter Dubsky, Ralf Kronenwett, Federico Rojo, Jack Cuzick, Martin Filipits, Amparo Ruiz, William Gradishar, Hatem Soliman, Lee Schwartzberg, Richard Buus, Dominik Hlauschek, Alvaro Rodríguez‑Lescure, Michael Gnant

Breast Cancer Research and Treatment published online April 2019

https://www.ncbi.nlm.nih.gov/pubmed/31041683

---

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)

The Lancet 2019 published online February 7, 2019.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)33137-4/fulltext

---

Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

Michael Gnant, Georg Pfeiler, Günther G Steger, Daniel Egle, Richard Greil, Florian Fitzal, Viktor Wette, Marija Balic, Ferdinand Haslbauer, Elisabeth Melbinger-Zeinitzer, Vesna Bjelic-Radisic, Raimund Jakesz, Christian Marth, Paul Sevelda, Brigitte Mlineritsch, Ruth Exner, Christian Fesl, Sophie Frantal, Christian F Singer, on behalf of the Austrian Breast and Colorectal Cancer Study Group

Lancet Oncol 2019 published online February 2019.

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30862-3/fulltext

---

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)

The Lancet, veröffentlicht online am 7. Februar 2019.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)33137-4/fulltext

---

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

Ingrid A. Mayer, Aleix Prat, Daniel Egle, Sibel Blau, J. Alejandro Perez Fidalgo, Michael Gnant, Peter A. Fasching, Marco Colleoni, Antonio C. Wolff, Eric P. Winer1, Christian F. Singer, Sara Hurvitz, Laura Garcia Estevez, Peter A. van Dam, Sherko Kümmel, Christoph Mundhenke, Frankie Holmes, Naveen Babbar, Laure Charbonnier, Ivan Diaz-Padilla, Florian D. Vogl, Dalila Sellami, Carlos L. Arteaga

Clin Cancer Res, published online February 5, 2019.

https://www.ncbi.nlm.nih.gov/pubmed/30723140

---

Konferenz-Beiträge 2019

Prevention and management of residual breast tissue following therapeutic and prophylactic radical mastectomy and skin-sparing and nipple-sparing mastectomy (POSTER)

Christine Deutschmann, Georg Pfeiler

San Antonio Breast Cancer Symposium, Dezember 2019

https://cancerres.aacrjournals.org/content/80/4_Supplement/OT3-06-01

---

Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from the LORELEI (Poster)

Paolo Nuciforo, Dominik Hlauschek, Cristina Saura, Evandro de Azambuja, Roberta Fasani, Patricia Villagrasa, Karoline Muehlbacher, Christos Sotiriou, Aleix Prat, Georg Pfeiler, Florentine Hilbers, Timothy R. Wilson, Junko Aimi, Thomas Stout, Vicente Valero, Christian Fesl, Jose Baselga, Michael Gnant, Martine Piccart, Fabrice Andre

2019 ASCO Annual Meeting, Juni 2019

https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.1050

Oncoplastic Breast Consortium consensus conference on nipplesparimg mastectomy

Weber W P, Haug M, Kurzeder Ch, Bjelic-Radisic V, Koller R, Reitsamer R, Fitzal F, Biazus J, Brenelli F, Urban C, Paulinelli R R, Blohmer JU, Heil J, Hoffmann J, Matrai Z, Catanuto G, Galimberti V, Gentilini O, Barry M, Hadar T, Allweis T M, Olsha O, Cardoso M J, Gouveia P F, Rubio I T, de Boniface J, Svensjö T, Bucher S, Dubsky P, Farhadi J, Fehlr M K, Fulco I, Ganz-Blättler, Günthert A, Harder Y, Hauser N, Kappos E A, Knauer M, Landin J, Mechera R, Meani F, Montagna G, Ritter M, Saccilotto R, Schwab F D, Steffens D, Tausch Ch, Zeindler J, Soysal S D, Lohsiriwat V, Kovac T, Tansley A, Wyld L, Romics L, El-Tamer M, Pusic A L, Sacchini V, Gnant M

Breast Cancer Research and Treatment
doi: 10.1007/s10549-018-4937-1

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245050/

---

High Accumulation of Metformin in Colonic Tissue of Subjects With Diabetes or the Metabolic Syndrome

Paleari L, Burhenne J, Weiss J, Foersch S, Roth W, Parodi A, Gnant M, Bachleitner-Hofmann T, Scherer D, Ulrisch C M, Stabuc B, Pununtoni M, Coccia G, Petrera M, Haefeli W E, Decensi A

Gastroenterology
doi: 10.1053/j.gastro.2017.12.040

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002843/

---

TP53 is not a prognostic marker—clinical consequences of a generally disregarded fact

Braunschmid T, Kührer I, Mittlböck M, Westerhoff M, Kappel-Latif Sonja, Brammen L, Krishnadath K K, Phillips W A, Gnant M, Kandioler D

Annals of the New York Academy of Sciences
doi: 10.1111/nyas.13947

https://nyaspubs.onlinelibrary.wiley.com/doi/pdf/10.1111/nyas.13947

---

Toward a Consensus on Centralization in Surgery

Vonlanthen R, Lodge P, Barkun J S, Farges O, Rogiers X, Soreide K, Kehlet H, Reynolds J V, Käser S A, Naredi P, Borel-Rinkes I, Biondo S, Pinto-Marques H, Gnant M, Nafteux P, Ryska M, Bechstein W O, Martel G, Dimick J B, Krawczyk M, Oláh A, Pinna A D, Popescu , Puolakkainen P A, Sotiropoulos G C, Tukiainen E J, Petrowsky H, Clavien AP

Annals of Surgery
doi: 10.1097/SLA.0000000000002965

https://insights.ovid.com/pubmed?pmid=30169394

---

Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial

Zeidan Y H, Habib J G, Ameye L, Paesmans M, de Azambuja E, Gelber R D, Campbell I, Nordenskjöld B, Gutiérez J, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Joseph D J, Crown J, Piccart-Gebhart M, Francis P A

International Journal of Radiation Oncology Biology Physics
doi.org/10.1016/j.ijrobp.2018.01.105

https://www.redjournal.org/article/S0360-3016(18)30230-X/pdf

---

Randomized clinical trial of the effect of a fibrin sealant patch on pancreatic fistula formation after pancreatoduodenectomy

Schindl M, Függer R, Götzinger P, Längle F, Zitt M, Stättner S, Kornprat P, Sahora K, Hlauschek D, Gnant M

British Journal of Surgery
DOI: 10.1002/bjs.10840

https://bjssjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/bjs.10840

---

Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study

Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Prichard K I, Gelber R D, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart M J, Dowsett M

Clinical Cancer Research
DOI: 10.1158/1078-0432.CCR-17-3473

https://clincancerres.aacrjournals.org/content/early/2018/03/10/1078-0432.CCR-17-3473

---

Explained variation in shared frailty models

Gleiss A, Gnant M, Schemper M

Statistics in Medicine
DOI: 10.1002/sim.7592

https://onlinelibrary.wiley.com/doi/pdf/10.1002/sim.7592

---

Impact of Breast Surgery in Primary Metastasized Breast Cancer Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial

Fitzal F, Bjelic-Radisic V, Knauer M, Steger G, Hubalek M, Balic M, Singer Ch, Bartsch R, Schrenk P, Soelkner L, Greil R, Gnant M

Annals of Surgery
DOI: 10.1097/SLA.0000000000002771

https://insights.ovid.com/pubmed?pmid=31082916

Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer

Singer CF, Tan YY, Fitzal F, Steger GG, Egle D, Reiner A, Rudas M, Moinfar F, Gruber C, Petru E, Bartsch R, Tendl KA, Fuchs D, Seifert M, Exner R, Balic M, Bago-Horvath Z, Filipits M, Gnant M

Clinical Cancer Research doi: 10.1158/1078-0432.CCR-16-2373

https://www.ncbi.nlm.nih.gov/pubmed/28143867

---

St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment

Gnant M, Harbeck N, Thomssen Ch

Breast Care 2017;12:102–107 DOI: 10.1159/000475698

https://www.karger.com/Article/Fulltext/475698

---

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy Ch, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J

The New England Journal of Medicine DOI: 10.1056/NEJMoa1703643

https://www.nejm.org/doi/full/10.1056/nejmoa1703643

---

Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence – A Phase II Study

Eisterer W, Piringer G, De Vries A, Öfner D, Greil R, Tschmelitsch J, Samonigg H, Sölkner L, Gnant M, Thaler J

Anticancer Research – International Journal of Cancer Research and Treatment doi:10.21873/anticanres.11xxx

https://www.ncbi.nlm.nih.gov/pubmed/28476845

---

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

Pan H, Gray R, Braybrooke J, Davies Ch, Taylor C, McGale P, Peto R, Pritchard K, Bergh J, Dowsett M, Hayes D

The New England Journal of Medicine DOI: 10.1056/NEJMoa1701830

https://www.nejm.org/doi/full/10.1056/NEJMoa1701830

---

Intensified preoperative chemoradiation by adding oxaliplatin in locally advanced, primary operable (cT3NxM0) rectal cancer

Kogler P, DeVries A, Eisterer W, Thaler J, Sölkner L, Öfner D

Journal of Radiation Oncology doi: 10.1007/s00066-017-1219-5

https://www.ncbi.nlm.nih.gov/pubmed/29127435

---

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O’Reilly S, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber R, Coates A, Di Leo A, Regan M, Goldhirsch A

The Lancet Oncology doi: 10.1016/S1470-2045(17)30715-5

https://www.ncbi.nlm.nih.gov/pubmed/2915801

---

Complexity of intermittent letrozole adjuvant therapy (Comment zu: Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial)

Chlebowski R, Pan K

The Lancet Oncology doi: 10.1016/S1470-2045(17)30854-9

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30854-9/fulltext

---

Rethinking Extended Adjuvant Antiestrogen Therapy to Increase Survivorship in Breast Cancer

Abderrahman B, Jordan VC

JAMA Oncology doi: 10.1001/jamaoncol.2017.3510

https://jamanetwork.com/journals/jamaoncology/article-abstract/2663286

---

A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients.

Piringer G, Fridrik M, Fridrik A, Leiherer A, Zabernigg A, Greil R, Eisterer W, Tschmelitsch J, Lang A, Frantal S, Burgstaller S, Gnant M, Thaler J

Support Care Cancer DOI: 10.1007/s00520-017-3961-8

https://www.ncbi.nlm.nih.gov/pubmed/29168033

---

Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor–Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial

Smith I, Yardley D, Burris H, De Boer R, Amadori D, McIntyre K, Ejlertsen B, Gnant M, Jonat W, Pritchard K, Dowsett M, Hart L, Poggio S, Comarella L, Salomon H, Wamil B, O’Shaughnessy J

Journal of Clinical Oncology DOI: 10.1200/JCO..69.2871

https://www.ncbi.nlm.nih.gov/pubmed/2811303

Effect of Tailored Dose-Dense Chemotherapy vs Standart 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer

Foukakis T, von Minckwitz G, Bengtsson N-O, Brandberg Y, Wallberg B, Fornander T, Mlineritsch B, Schmatloch S, Singer C, Steger G, Egle D, Karlsson E, Carlsson L, Loibl S, Untch M, Hellström M, Johansson H, Anderson H, Malmström P, Gnant M, Greil R, Möbus V, Bergh J

Jama Original Investigation. ;316(18):1-9. doi:10.1001/jama..15865

https://www.ncbi.nlm.nih.gov/pubmed/27825007